» Articles » PMID: 1954574

Serotypes and Subtypes of Neisseria Meningitidis Serogroup B Strains Associated with Meningococcal Disease in Canada, 1977-1989

Overview
Journal Can J Microbiol
Specialty Microbiology
Date 1991 Aug 1
PMID 1954574
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Typing of Neisseria meningitidis serogroup B disease isolates was carried out using a panel of serotype-and subtype-specific monoclonal antibodies (MAbs) in enzyme-linked immunosorbent assays (ELISA). Three hundred and sixty-two strains isolated from 1977 to 1986 were typed using five serotyping and seven subtyping reagents and outer membrane vesicles as antigens. Serotype 2b accounted for 30% of the disease isolates. The most common subtype was P1.2, which occurred on 18.5% of all strains or 48.6% of the serotype 2b strains. Of the 362 strains typed, 135 (37.3%) were serotyped and 122 (33.7%) were subtyped. Overall, 185 (51.1%) of the strains could be assigned a serotype and (or) subtype. Strains (221) isolated during the years 1987-1989 were typed using a panel of 6 serotyping and 12 subtyping reagents by whole-cell ELISA. Strains of serotypes 4 (21.7%) and 15 (20.8%) were the most common and carried a wide variety of subtypes. The most common subtypes were P1.2 (11.8%) and P1.16 (9.5%). Of the 221 strains analyzed, 132 (59.7%) were assigned a serotype and 123 (55.7%) a subtype and with all 18 MAbs, 192 (86.9%) of the strains were serotyped and (or) subtyped. Two different MAbs to the four epitopes 2a, 15, P1.2, and P1.16 gave discordant reactions of 0.3, 6.6, 2.6, and 2.2%, respectively, when used to analyze over 300 strains of N. meningitidis.

Citing Articles

Enhanced surveillance of invasive meningococcal disease in Canada, 2006-2011.

Li Y, Tsang R, Desai S, Deehan H Can Commun Dis Rep. 2018; 40(9):160-169.

PMID: 29769898 PMC: 5864469. DOI: 10.14745/ccdr.v40i09a01.


Potential capsule switching from serogroup Y to B: The characterization of three such Neisseria meningitidis isolates causing invasive meningococcal disease in Canada.

Tsang R, Law D, Tyler S, Stephens G, Bigham M, Zollinger W Can J Infect Dis Med Microbiol. 2007; 16(3):171-4.

PMID: 18159539 PMC: 2095022. DOI: 10.1155/2005/216369.


Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.

Zhu D, Zhang Y, Barniak V, Bernfield L, Howell A, Zlotnick G Infect Immun. 2005; 73(10):6838-45.

PMID: 16177362 PMC: 1230910. DOI: 10.1128/IAI.73.10.6838-6845.2005.


Vaccine potential of the Neisseria meningitidis 2086 lipoprotein.

Fletcher L, Bernfield L, Barniak V, Farley J, Howell A, Knauf M Infect Immun. 2004; 72(4):2088-100.

PMID: 15039331 PMC: 375149. DOI: 10.1128/IAI.72.4.2088-2100.2004.


Invasive meningococcal disease in Scotland, 1994 to 1999, with emphasis on group B meningococcal disease.

Kyaw M, Clarke S, Christie P, Jones I, Campbell H J Clin Microbiol. 2002; 40(5):1834-7.

PMID: 11980971 PMC: 130913. DOI: 10.1128/JCM.40.5.1834-1837.2002.